tbuckley/cabot-search huggingface dataset:
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study
Authors: Panagiotis Baliakas, Anastasia Hadzidimitriou, Lesley-Ann Sutton, Eva Minga, Andreas Agathangelidis, Michele Nichelatti, Athina Tsanousa, Lydia Scarfò, Zadie Davis, Xiao-Jie Yan, Tait Shanafelt, Karla Plevova, Yorick Sandberg, Fie Juhl Vojdeman, Myriam Boudjogra, Tatiana Tzenou, Maria Chatzouli, Charles C Chu, Silvio Veronese, Anne Gardiner, Larry Mansouri, Karin E Smedby, Lone Bredo Pedersen, Kirsten van Lom, Véronique Giudicelli, Hana Skuhrova Francova, Florence Nguyen-Khac, Panagiotis Panagiotidis, Gunnar Juliusson, Lefteris Angelis, Achilles Anagnostopoulos, Marie-Paule Lefranc, Monica Facco, Livio Trentin, Mark Catherwood, Marco Montillo, Christian H Geisler, Anton W Langerak, Sarka Pospisilova, Nicholas Chiorazzi, David Oscier, Diane F Jelinek, Nikos Darzentas, Chrysoula Belessi, Frederic Davi, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos
Journal: The Lancet Haematology (2014)
Autoantibody and idiotype profile of lung involvement in autoimmune rheumatic disease.
Authors: L Turner-Stokes, P Haslam, M Jones, C Dudeney, S Le Page, D Isenberg
Journal: Annals of the Rheumatic Diseases (1990)

Several reports have linked the presence of certain serum autoantibodies with particular clinical manifestations of autoimmune disease. For example, the Jo-1 antibody is now established as a marker for fibrosing alveolitis in polymyositis. To investigate the possible association of further autoantibodies or idiotypes with fibrosing alveolitis in autoimmune rheumatic disease a panel of autoantibodies was measured in serum samples from 28 patients with systemic lupus erythematosus (SLE) (10 with and 18 without lung involvement), 21 patients with scleroderma (12 with fibrosing alveolitis and nine without), and 41 patients with 'lone' fibrosing alveolitis. Antibodies measured were IgM and IgG anti-dsDNA and anti-ssDNA antibody; IgG and IgM anticardiolipin antibody; anti-poly (ADP-ribose) antibody; antibodies to two common idiotypes of anti-DNA antibodies, designated 134 and 16/6; and IgM, IgG, and IgA isotypes of rheumatoid factor. None of these antibodies was specifically associated with lung involvement in SLE or scleroderma, but a trend was found towards an increase in all autoantibodies in association with lung disease in SLE, while the reverse trend was seen in scleroderma.
Challenges and key research questions for yaws eradication
Authors: Michael Marks, Oriol Mitjà, Lasse S Vestergaard, Allan Pillay, Sascha Knauf, Cheng-Yen Chen, Quique Bassat, Diana L Martin, David Fegan, Fasihah Taleo, Jacob Kool, Sheila Lukehart, Paul M Emerson, Anthony W Solomon, Tun Ye, Ronald C Ballard, David C W Mabey, Kingsley B Asiedu
Journal: The Lancet Infectious Diseases (2015)
THE TREATMENT OF BALDNESS WITH HOMOLOGOUS PUNCH GRAFTS.
Authors: PHILIP LEBON
Journal: British Journal of Dermatology (1963)

Journal Article THE TREATMENT OF BALDNESS WITH HOMOLOGOUS PUNCH GRAFTS. Get access PHILIP LEBON, F.R.C.S. PHILIP LEBON, F.R.C.S. Late Surgical Registrar, Highlands General Hospital, Southgate, London, N.21 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 75, Issue 4, 1 April 1963, Pages 170–172, https://doi.org/10.1111/j.1365-2133.1963.tb13962.x Published: 01 April 1963
Regression of Existing Glomerulosclerosis by Inhibition of Aldosterone
Authors: Jean Claude Aldigier, Talerngsak Kanjanbuch, Li-Jun Ma, Nancy J. Brown, Agnes B. Fogo
Journal: Journal of the American Society of Nephrology (2005)

In this study, the effects of inhibition of aldosterone on regression of existing hypertension-related glomerulosclerosis were investigated. Adult male Sprague Dawley rats (220 to 250 g) underwent 5/6 nephrectomy (Nx). Severity of glomerulosclerosis was assessed by renal biopsy 8 wk later, and rats were divided into four groups with equal biopsy sclerosis and then randomized by group to 4-wk treatments as follows: Control with no further treatment (CONT; <i>n</i> = 6); spironolactone (SP) alone (200 mg/kg per d, by gavage, <i>n</i> = 6); or SP combined with nonspecific triple antihypertensive drugs (TRX; reserpine, hydralazine, and hydrochlorothiazide in drinking water; SP+TRX, <i>n</i> = 7) or with angiotensin type 1 receptor antagonist (AT1RA; losartan in drinking water; SP+AT1RA, <i>n</i> = 8). When the rats were killed 12 wk after Nx, autopsy glomerulosclerosis index (SI; 0 to 4+ scale) was compared with biopsy SI in the same rats. Systolic BP was increased at 8 wk after Nx and continued to increase at 12 wk after Nx in the CONT and SP groups but not in SP+TRX- or SP+AT1RA-treated rats. Serum creatinine at 12 wk was significantly decreased in all SP-treated groups <i>versus</i> CONT. CONT rats had on average a 157% increase in SI from biopsy to killing at 12 wk, compared with only 84% increase in SP rats, with regression of SI in some rats. The effects on glomerulosclerosis by SP were further enhanced (when systolic BP was controlled by TRX or by AT1RA). It is concluded that inhibition of aldosterone by SP not only slows development of glomerulosclerosis but also induces regression in some rats of existing glomerulosclerosis.
The efficacy of a supervised and a home-based core strengthening programme in adults with poor core stability: a three-arm randomised controlled trial
Authors: V H Chuter, X A K Janse de Jonge, B M Thompson, R Callister
Journal: British Journal of Sports Medicine (2014)

Background Poor core stability is linked to a range of musculoskeletal pathologies and core-strengthening programmes are widely used as treatment. Treatment outcomes, however, are highly variable, which may be related to the method of delivery of core strengthening programmes. We investigated the effect of identical 8 week core strengthening programmes delivered as either supervised or home-based on measures of core stability. Methods Participants with poor core stability were randomised into three groups: supervised (n=26), home-based (n=26) or control (n=26). Primary outcomes were the Sahrmann test and the Star Excursion Balance Test (SEBT) for dynamic core stability and three endurance tests (side-bridge, flexor and Sorensen) for static core stability. The exercise programme was devised and supervised by an exercise physiologist. Results Analysis of covariance on the change from baseline over the 8 weeks showed that the supervised group performed significantly better on all core stability measures than both the home-based and control group. The home-based group produced significant improvements compared to the control group in all static core stability tests, but not in most of the dynamic core stability tests (Sahrmann test and two out of three directions of the SEBT). Conclusions Our results support the use of a supervised core-strengthening programme over a home-based programme to maximise improvements in core stability, especially in its dynamic aspects. Based on our findings in healthy individuals with low core stability, further research is recommended on potential therapeutic benefits of supervised core-strengthening programmes for pathologies associated with low core stability. Trial registration number ACTRN12613000233729.
Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to g145r and other naturally occurring “a” loop escape mutations
Authors: Michel P. Cooreman, Mark H. van Roosmalen, René te Morsche, Cécile M. G. Sünnen, Esther M. E. Schoondermark-van de Ven, Jan B. M. J. Jansen, Guido N. J. Tytgat, Pauline L. M. de Wit, Wilma P. Paulij
Journal: Hepatology (1999)

The hepatitis B surface antigen (HBsAg) "a" domain harbors major B-cell epitopes. Viruses with mutations in this region emerge after vaccination or during hepatitis B immune globulin (HBIg) prophylaxis. A strain with G145R replacement has been almost invariably isolated as a major escape mutant. We investigated mutant antigen-antibody interactions with direct binding assays. G145R and 16 other naturally occurring recombinant HBsAg mutants were expressed in mammalian Cos-1 cells. The reactivity of a panel of 28 murine anti-hepatitis B surface antigen (anti-HBs) monoclonal antibodies to mutant antigens was measured with enzyme immunoassay and expressed as percentage compared with the wild-type (wt) HBsAg signal for each antibody. All point-mutated proteins displayed diffuse intracellular immunofluorescent labeling corresponding to a secretory pathway. Monoclonal antibodies (mAbs) were classified according to different binding patterns. The effect of mutations on antibody binding differs depending on the amino acid involved and on the location within the "a" loop. As expected, most antibodies had absent or negligible binding (<40%), notably with residue 145 replacements. However, we identified antibodies that reacted with conformational epitopes but nevertheless had adequate reactivity (>40%) with all mutant antigens, including G145R. The effect of G145R was more pronounced than that of G145A. A subgroup of antibodies had substantially increased recognition (>120%) of antigens with mutations in the first loop. We demonstrated that antibodies can be selected or combined that react with all mutants investigated, including G145R. These data offer perspectives for improving anti-HBs-based protection against hepatitis B.
Feasibility of continuous oxygen delivery and cardiac output measurement by application of the Fick principle.
Authors: P J Feustel, R J Perkins, J E Oppenlander, H H Stratton, I L Cohen
Journal: American Journal of Respiratory and Critical Care Medicine (1994)

Continuous mixed venous oxygen saturation (SVO2) measurements from fiberoptic pulmonary artery catheters, arterial oxygen saturation (SaO2) measurements from pulse oximetry, and minute-by-minute oxygen consumption (VO2) measurements from indirect calorimetry can be used for near-continuous estimation of cardiac output (Qt) and oxygen delivery (DO2) by application of the Fick Principle. Assumptions required for calculation of blood oxygen contents include constant hemoglobin concentration (Hgb) and constant or negligible physically dissolved oxygen. First, the influence of these assumptions on continuous Qt and DO2 determinations was tested. Unmeasured changes in Hgb resulted in substantial error in calculated Qt, whereas calculated DO2 was minimally affected. Both Qt and DO2 were little altered by errors in PaO2 or PVO2. Second, the effects of SVO2, SaO2, and VO2 measurement errors on Qt and DO2 calculations under normal and extreme conditions were quantified. Relative errors in SVO2 were increased by a factor of 4.2 in Qt estimations and by a factor of 3.2 in DO2 measurements under normal conditions. These factors increased with increasing SVO2, and thus, Qt and DO2 became increasingly unreliable as oxygen extraction fell. Third, we compared continuous measurements of Qt and DO2 with intermittent measurements made by thermodilution cardiac output and blood sampling, and found correlation coefficients of 0.85 for Qt and 0.89 for DO2. Fourth, common measurement errors in VO2 and DO2 calculated in this way were found to bias regressions between VO2 and DO2, and this bias could be minimized only if the DO2 range were high and SVO2 were low.(ABSTRACT TRUNCATED AT 250 WORDS)
Prostatic Acid Phosphatase Is Not a Prostate Specific Target
Authors: Ileana B. Quintero, César L. Araujo, Anitta E. Pulkka, Riikka S. Wirkkala, Annakaisa M. Herrala, Eeva-Liisa Eskelinen, Eija Jokitalo, Pekka A. Hellström, Hannu J. Tuominen, Pasi P. Hirvikoski, Pirkko T. Vihko
Journal: Cancer Research (2007)

Abstract Prostatic acid phosphatase (PAP) is currently evaluated as a target for vaccine immunotherapy of prostate cancer. This is based on the previous knowledge about secretory PAP and its high prostatic expression. We describe a novel PAP spliced variant mRNA encoding a type I transmembrane (TM) protein with the extracellular NH2-terminal phosphatase activity and the COOH-terminal lysosomal targeting signal (YxxΦ). TM-PAP is widely expressed in nonprostatic tissues like brain, kidney, liver, lung, muscle, placenta, salivary gland, spleen, thyroid, and thymus. TM-PAP is also expressed in fibroblast, Schwann, and LNCaP cells, but not in PC-3 cells. In well-differentiated human prostate cancer tissue specimens, the expression of secretory PAP, but not TM-PAP, is significantly decreased. TM-PAP is localized in the plasma membrane-endosomal-lysosomal pathway and is colocalized with the lipid raft marker flotillin-1. No cytosolic PAP is detected. We conclude that the wide expression of TM-PAP in, for instance, neuronal and muscle tissues must be taken into account in the design of PAP-based immunotherapy approaches. [Cancer Res 2007;67(14):6549–54]
Progress in Defining CD4 Helper Cell Responses in Chronic Viral Infections
Authors: Cheryl L. Day, Bruce D. Walker
Journal: The Journal of Experimental Medicine (2003)

Infection with the AIDS virus has led to an expanding global health crisis, with over 45 million persons currently living with HIV infection. Ineffective immune control and resultant disease progression is a hallmark of this infection, despite the induction of vigorous virus-specific CD8 T cell
Long-term follow-up after surgical treatment of obstructive sleep apnoea by maxillomandibular advancement
Authors: R Conradt, W Hochban, U Brandenburg, J Heitmann, JH Peter
Journal: European Respiratory Journal (1997)

Obstructive sleep apnoea (OSA) is a common disorder with potentially serious consequences. If maxillary and mandibular deficiency, often in combination with a narrow posterior airway space is present, therapy of OSA by maxillomandibular osteotomy is possible. However, long-term follow-up of patients undergoing these procedures is lacking. We present the results of 15 OSA patients (1 female and 14 males), who underwent maxillomandibular advancement surgery with a follow-up of at least 2 yrs. Polysomnography was performed before surgery, after 6-12 weeks, and 1 and 2 yrs postoperatively. Mean apnoea/hypopnoea index (AHI) decreased from 51.4 events.h-1 before therapy to 5.0 events.h-1 6 weeks postoperatively, and was 8.5 events.h-1 after 2 yrs. Oxygen saturation significantly increased following surgery. After 2 yrs, the AHI was &lt; 10 events.h-1 in 12 out of 15 subjects. No significant changes were found comparing the 6-12 weeks versus the 2 year follow-up data. The significant increase in stage 3/4 non-rapid eye movement (NREM) sleep and decrease in stage 1 NREM sleep, indicative of the restoration of normal physiological sleep structure, persisted in 14 of the 15 subjects 2 yrs postoperatively. Three patients, however, did not show satisfactory improvement 2 yrs postoperatively; two showed obstructive and one central respiratory events. This study demonstrates that maxillomandibular advancement is successful in a high percentage of patients carefully selected by cephalometric and polysomnographic investigation. Postoperative success has proved to be stable over a period of 2 yrs. Further preoperative evaluation seems necessary in patients with predominantly mixed or central apnoeas.
Lack of association of MYO9B genetic variants with coeliac disease in a British cohort
Authors: K A Hunt
Journal: Gut (2006)

<b>Background and aims:</b> Development of coeliac disease involves an interaction between environmental factors (especially dietary wheat, rye, and barley antigens) and genetic factors (there is strong inherited disease susceptibility). The known human leucocyte antigen (<i>HLA</i>)<i>-DQ2</i> and <i>-DQ8</i> association explains only a minority of disease heritability. A recent study in the Dutch population suggested that genetic variation in the 3′ region of myosin IXB (<i>MYO9B</i>) predisposes to coeliac disease. MYO9B is a Rho family GTPase activating protein involved in epithelial cell cytoskeletal organisation. MYO9B is hypothesised to influence intestinal permeability and hence intestinal antigen presentation. <b>Methods:</b> Four single nucleotide polymorphisms were chosen to tag all common haplotypes of the <i>MYO9B</i> 3′ haplotype block (exons 15–27). We genotyped 375 coeliac disease cases and 1366 controls (371 healthy and 995 population based). All individuals were of White UK Caucasian ethnicity. <b>Results:</b> UK healthy control and population control allele frequencies were similar for all <i>MYO9B</i> variants. Case control analysis showed no significant association of any variant or haplotype with coeliac disease. <b>Conclusions:</b> Genetic variation in <i>MYO9B</i> does not have a major effect on coeliac disease susceptibility in the UK population. Differences between populations, a weaker effect size than originally described, or possibly a type I error in the Dutch study might explain these findings.
Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
Authors: Liping L. Sun, Diego Ellerman, Mary Mathieu, Maria Hristopoulos, Xiaocheng Chen, Yijin Li, Xiaojie Yan, Robyn Clark, Arthur Reyes, Eric Stefanich, Elaine Mai, Judy Young, Clarissa Johnson, Mahrukh Huseni, Xinhua Wang, Yvonne Chen, Peiyin Wang, Hong Wang, Noel Dybdal, Yu-Waye Chu, Nicholas Chiorazzi, Justin M. Scheer, Teemu Junttila, Klara Totpal, Mark S. Dennis, Allen J. Ebens
Journal: Science Translational Medicine (2015)

Anti-CD20/CD3 T cell–dependent bispecific antibodies may be useful for the treatment of B cell malignancies.
Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia
Authors: Joris Berwaerts, Yanning Liu, Srihari Gopal, Isaac Nuamah, Haiyan Xu, Adam Savitz, Danielle Coppola, Alain Schotte, Bart Remmerie, Nataliya Maruta, David W. Hough
Journal: JAMA Psychiatry (2015)

Treatment nonadherence and relapse are common problems in patients with schizophrenia.The long-acting 3-month formulation of paliperidone palmitate, owing to its extended elimination half-life, may offer a valuable therapeutic option for these patients.OBJECTIVE To evaluate the efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo in delaying time to relapse of schizophrenia symptoms.DESIGN, SETTING, AND PARTICIPANTS This randomized, multicenter trial conducted from April 26, 2012, through April 9, 2014, in 8 countries consisted of 4 phases: 3-week screening phase, flexible-dose 17-week open-label transition phase, 12-week open-label maintenance phase, and open-ended double-blind (DB) phase.Of the 506 patients enrolled (aged 18-70 years; DSM-IV-TR diagnosis of schizophrenia), 305 were randomized to 3-month paliperidone palmitate (n = 160) or placebo (n = 145) in the DB phase.INTERVENTIONS Patients received once-monthly doses of the 1-month formulation of paliperidone palmitate (50, 75, 100, or 150 mg eq) during the transition phase, followed by a single dose of the 3-month formulation (3.5 times the stabilized dose of once-monthly paliperidone palmitate) during the maintenance phase.Stabilized patients were randomized to receive either a fixed dose of 3-month paliperidone palmitate (175, 263, 350, or 525 mg eq) or placebo once every 3 months during the DB phase.MAIN OUTCOMES AND MEASURES Time from randomization to the first relapse event (time to relapse) in the DB phase. RESULTSIn the interim analysis, time to first relapse was significantly different in favor of the paliperidone palmitate group vs the placebo group (hazard ratio = 3.45; 95% CI, 1.73-6.88;P < .001);median time to relapse was 274 days for placebo but not estimable for 3-month paliperidone palmitate.An independent data monitoring committee recommended early study termination due to efficacy.In the DB phase, 183 of 305 patients (62% with 3-month paliperidone palmitate; 58% with placebo) had at least 1 treatment-emergent adverse event; those noted more frequently in the group receiving paliperidone palmitate than in the placebo group were headache (9% vs 4%), weight increased (9% vs 3%), nasopharyngitis (6% vs 1%), and akathisia (4% vs 1%). CONCLUSIONS AND RELEVANCECompared with placebo, the 3-month formulation of paliperidone palmitate administered 4 times yearly significantly delayed time to relapse in patients with schizophrenia.The 3-month formulation was generally tolerable and has a safety profile consistent with other marketed paliperidone formulations.
The acoustic properties of capsaicin-induced cough in healthy subjects
Authors: MJ Doherty, LJ Wang, S Donague, MG Pearson, P Downs, SA Stoneman, JE Earis
Journal: European Respiratory Journal (1997)

Acoustic analysis of cough both in the time and frequency domain has been reported using voluntary and spontaneous cough. The main aim of this study was to discover whether such analysis of capsaicin-induced cough enables differences between normal subjects to be recognized. We present data from 13 healthy subjects (with normal lung function and no history of respiratory disease) using a new method of acoustic analysis, which presents the data in three graphical forms: 1) spectrogram; 2) overall spectral energy, 3) root mean square (RMS) pressure plots. Using the RMS sound pressure traces, different subjects had either two peaks, a single peak or multiple peaks. The occurrence of single and multiple peaks has previously been associated with disease states but we found them in normal subjects. The number of peaks and the visual pattern of the spectrogram was reproducible within and specific to each individual over time. During a peal of coughs in a single expiration, the peak amplitude of successive coughs decreased as lung volume reduced. Despite similarities in the overall spectral energy between individuals, there were marked differences in the small visual details of the spectrograms. However, in an individual, these small details were remarkably constant both within and between days, and can be regarded as a "cough signature". This type of spectrographic analysis provides a new approach to the analysis both of normal and abnormal cough sounds, and has identified similarities and differences in capsaicin-induced cough in normal individuals. It has potential as a tool with which to study the pathophysiology of cough.
Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score
Authors: Alessandro Consolaro, Nicolino Ruperto, Giulia Bracciolini, Alessia Frisina, Maria Chiara Gallo, Angela Pistorio, Sara Verazza, Giorgia Negro, Valeria Gerloni, Claudia Goldenstein-Schainberg, Flavio Sztajnbok, Nico M Wulffraat, Alberto Martini, Angelo Ravelli
Journal: Annals of the Rheumatic Diseases (2013)

To determine cutoff values for defining the state of high disease activity (HDA) in juvenile idiopathic arthritis (JIA) using the Juvenile Arthritis Disease Activity Score (JADAS).For the selection of cutoff values, data from a clinical database including 609 patients were used. Optimal cutoff values were determined against external criteria by calculating the 25th and 10th centile of cumulative score distribution and through receiver operating characteristic curve analysis. External criteria were based on the therapeutic decision made by the attending doctor. Cross-validation was performed using five patient samples that included 1421 patients.The optimal cutoff values were those obtained through the 90% fixed sensitivity method. The selected JADAS cutoff values were the following: 4.2 and 8.5 for JADAS27 in oligoarthritis and polyarthritis, respectively; 4.2 and 10.5 for both JADAS10 and JADAS71 in oligoarthritis and polyarthritis, respectively. In cross-validation analyses, the cutoff values showed strong ability to discriminate between different levels of American College of Rheumatology paediatric response in two clinical trials and could predict worse functional and radiographic outcome.Cutoff values for classifying HDA in JIA using the JADAS were developed. In cross-validation analyses, they proved to have good construct and discriminant validity and ability to predict disease outcome.